Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia

@article{Matthews2001PatternsOF,
  title={Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia},
  author={Jane P. Matthews and James F. Bishop and Graham A R Young and Surender K Juneja and Ray M. Lowenthal and O. Margaret Garson and Ralph Cobcroft and Anthony J. Dodds and Arno Enno and E. A. Gillett and Reichenspurner Hermann and Douglas Edgar Joshua and David D. F. Ma and Jeffrey Szer and Kerry McDonald Taylor and Max M Wolf and Km Bradstock},
  journal={British Journal of Haematology},
  year={2001},
  volume={113}
}
Patterns of failure were studied in two consecutive randomized trials of intensified induction therapy carried out by the Australian Leukaemia Study Group (ALSG) between 1984 and 1991 to determine the impact of dose intensification. Patients received standard dose cytarabine and daunorubicin (7‐3), 7‐3 plus etoposide (7‐3‐7) or 7‐3 plus high‐dose cytarabine (HIDAC‐3‐7) chemotherapy. Patients with FAB M3 morphology were excluded. Time to failure (TTF) was defined as the time from randomization… Expand
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
TLDR
Intensive induction chemotherapy incorporating high-dose cytarabine results in high complete remission rates, but further intensive consolidation treatment does not appear to confer additional benefit. Expand
High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
TLDR
HDAC treatment led to lower relapse rate in induction and consolidation therapy than SDAC treatment, especially for the favorable-risk group, and Auto-BMT/allo- BMT was more beneficial in prolonging RFS than HDAC. Expand
Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant
TLDR
The clofarabine-AraC salvage strategy combines pronounced anti-leukemic activity with an acceptable toxicity profile and allows the majority of patients with relapsed or refractory AML to proceed to allo-SCT, even in cytogenetically defined high risk situations. Expand
The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes
TLDR
With the availability of a platelet growth factor, recombinant human interleukin (IL)-11, an effective way to prevent chemotherapy-induced thrombocytopenia and accelerate platelet recovery, can now be provided to patients. Expand
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
TLDR
The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care, despite Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. Expand
Impairment in functional status and survival in patients with acute myeloid leukaemia
TLDR
In patients with AML, FS and not age is a major predictor of survival and the influence of FS is independent from cytogenetic risk group, and impaired KPS and IADL significantly influenced median survival in univariate analysis. Expand
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
TLDR
This study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3. Expand
Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
TLDR
The indications for allogeneic transplants in AML are reviewed and reduced-intensity conditioning regimens are discussed, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Expand
The prevalent predicament of relapsed acute myeloid leukemia.
  • J. Szer
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2012
TLDR
All patients with relapsed AML should be considered for an appropriate clinical trial and a decision made about the appropriateness of intensive therapy and whether a potentially curative allogeneic stem cell transplantation (allo-SCT) is possible. Expand
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
TLDR
The leukaemic cell burden influences the plasma concentrations of anthracyclines, and analysis of plasma DNR and the metabolite daunorubicinol (DOL) concentrations in patients with a high WBC count support that the low DNR/DOL concentrations are due a distribution effect. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
TLDR
It is concluded that a dose-effect exists for cytarabine in AML and that HIDAC-3-7 prolongs remission duration and disease-free survival and is tolerable when used as initial induction therapy in patients with de novo AML. Expand
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
TLDR
These studies provide clinical evidence that a dose-response effect is present for cytarabine in AML, and it is likely that remission duration may be a useful clinical tool to study the influence of new induction therapies on residual resistant leukemia. Expand
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
TLDR
These findings support the use of pretreatment cytogenetics in risk stratification of postremission AML therapy and demonstrate that the curative impact of cytarabine intensification varies significantly among cytogenetic groups and results in a substantial prolongation of CR among patients with CBF and normal karyotypes, but not in those with other karyotypic abnormalities. Expand
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
TLDR
High-dose versus standard-dose cytarabine proved a safe and effective strategy and a new way of delivering early intensification treatment for AML and may contribute a specific benefit to poor-risk patients that requires further substantiation. Expand
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
TLDR
It is concluded that, at the doses and schedule used in this study, A + I is superior to A + D for induction therapy of AML in adults. Expand
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
TLDR
The addition of etoposide to a high-dose cytosine arabinoside regimen had at best a marginal effect at the expense of some increase in toxicity. Expand
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
TLDR
Induction and consolidation therapy intensified with etoposide resulted in significantly improved remission duration but not survival, and in older patients, 7-3-7 was more toxic, with significantly more severe [World Health Organization (WHO) grade 3 or 4] stomatitis and no additional clinical benefit. Expand
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
TLDR
The concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger is supported and the results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission. Expand
Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.
TLDR
Detailed cytogenetic analyses were performed on specimens from 198 patients with de novo acute nonlymphocytic leukemia, including high-resolution banding studies in 79 patients, suggesting patients with abnormalities associated with poor responses may be considered for investigational approaches and may provide insights into mechanisms of drug resistance. Expand
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
TLDR
Patients who received both HDAC induction and consolidation had the best postremission outcomes; however, the proportion of CR patients who did not go on to protocol consolidation therapy was more than twice as high afterHDAC induction compared with SDAC. Expand
...
1
2
3
4
...